Drug Profile
Research programme: type 5 adenylyl cyclase inhibitors - Vasade Biosciences
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Vasade Biosciences
- Class Heart failure therapies; Small molecules
- Mechanism of Action Adenylate cyclase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Heart failure in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Heart-failure in USA
- 21 Jul 2016 Preclinical trials in Heart failure in USA (unspecified route)